Replies to post #3276 on Seelos Therapeutics Inc (SEEL)

[califax]

Northeast Securities Issues Investment Opinion on Apricus Biosciences, Inc. (APRI)

Date : 10/27/2010 @ 10:30AM
Source : Business Wire
Stock : Northeast Securities (APRI)

http://ih.advfn.com/p.php?pid=nmona&article=44956844

Northeast Securities published an initiation of coverage research report on Apricus Biosciences, Inc. (APRI) with an Attractive rating and a 12-month price target of $4.50 on September 2, 2010. A subsequent research note was published updating clinical and financial developments and reiterating the Attractive rating with a new $4.00 12-month price target on October 22, 2010.

*Industry: Pharmaceuticals & Biotechnology

*Current Rating: Attractive

*Current Rating Assigned: 10-22-2010

*Closing Price: $1.72

*Current Target Price (12months): $4.00

*Analyst: Harry Russell

Additional information on these reports including all regulatory disclosures may be obtained by contacting Northeast Securities.

About Northeast Securities

Northeast Securities is a privately held New York based firm which provides a full complement of Investment Banking services as well as Institutional Sales, Trading and Research. A Northeast Securities research report or note is not intended as an offering or solicitation of an offer to buy or sell the securities mentioned or discussed. Northeast Securities is a member of FINRA and the SIPC.